PL396633A1 - The use of α-ketoglutarate for the production a drug used in anti-cancer therapy - Google Patents
The use of α-ketoglutarate for the production a drug used in anti-cancer therapyInfo
- Publication number
- PL396633A1 PL396633A1 PL396633A PL39663311A PL396633A1 PL 396633 A1 PL396633 A1 PL 396633A1 PL 396633 A PL396633 A PL 396633A PL 39663311 A PL39663311 A PL 39663311A PL 396633 A1 PL396633 A1 PL 396633A1
- Authority
- PL
- Poland
- Prior art keywords
- ketoglutarate
- production
- cancer therapy
- cancer
- drug used
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Przedmiotem wynalazku jest zastosowanie ?-ketoglutaranu, w postaci nanoproszku otrzymanego w wyniku modyfikacji ?-ketoglutaranu plazma o czestotliwosci radiowej w atmosferze metanu, do wytwarzania leku hamujacego niekontrolowane namnazanie komórek nowotworowych. Stwierdzono antyproliferacyjne, czyli hamujace rozwój nowotworu na poziomie in vitro, dzialanie ?-ketoglutaranu na poziomie dysregulacji podzialu komórki nowotworowej z fazy G1 mitozy (poczatek podzialu) do fazy S (aktywnej syntezy bialek nowotworowych).The subject of the invention is the use of β-ketoglutarate, in the form of nanopowder obtained as a result of modification of β-ketoglutarate plasma with radio frequency in the methane atmosphere, for the preparation of a drug which inhibits the uncontrolled multiplication of cancer cells. Anti-proliferative, i.e. inhibiting the development of cancer at the in vitro level, activity of β-ketoglutarate at the level of dysregulation of the tumor cell division from the G1 phase of mitosis (the beginning of division) to the S phase (active synthesis of cancer proteins) was found.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL396633A PL217053B1 (en) | 2011-10-14 | 2011-10-14 | The use of α-ketoglutarate for the production a drug used in anti-cancer therapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL396633A PL217053B1 (en) | 2011-10-14 | 2011-10-14 | The use of α-ketoglutarate for the production a drug used in anti-cancer therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
PL396633A1 true PL396633A1 (en) | 2013-04-15 |
PL217053B1 PL217053B1 (en) | 2014-06-30 |
Family
ID=48536341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL396633A PL217053B1 (en) | 2011-10-14 | 2011-10-14 | The use of α-ketoglutarate for the production a drug used in anti-cancer therapy |
Country Status (1)
Country | Link |
---|---|
PL (1) | PL217053B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11241455B2 (en) | 2016-01-15 | 2022-02-08 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Methods of treating disease by metabolic control of T-cell differentiation |
-
2011
- 2011-10-14 PL PL396633A patent/PL217053B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL217053B1 (en) | 2014-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502839A1 (en) | Antiviral compounds | |
GT201500051A (en) | GLUCOSILCERAMIDE SINTASA INHIBITORS | |
CR20150370A (en) | ANTIVIRAL COMPOUNDS | |
PH12014501561A1 (en) | Therapeutically active compounds and their methods of use | |
CR20200479A (en) | Therapeutically active compounds and their methods of use | |
EA201490707A1 (en) | MACRO CYCLIC INHIBITORS FLT3 KINASE | |
MX345928B (en) | Therapeutically active compositions and their methods of use. | |
EA201490891A1 (en) | PYRIDOPYRAZINS, possessing anti-cancer activity through inhibition of FGFR kinase | |
EA201490636A1 (en) | T-CELLS DESIGNED WITH THE HELP OF RNA FOR THE TREATMENT OF MALIGNOUS NON-FORMATIONS | |
BR112015000399A2 (en) | pyrazolyl pyrimidine derivatives | |
MY162950A (en) | Compounds and methods for kinase modulation, and indications therefor | |
EA201390381A1 (en) | TRIAZINOXADIAZOLES | |
MX350539B (en) | Enediyne compounds, conjugates thereof, and uses and methods therefor. | |
EA201591545A1 (en) | C-3 ALKYL AND ALKENYL-MODIFIED BETULINIC ACID DERIVATIVES | |
MX2015012731A (en) | Processes and intermediates for preparing a medicament. | |
EA201391114A1 (en) | METHODS OF USE ALK-INHIBITORS | |
MX2013010898A (en) | Novel pyrimidine derivatives. | |
NZ704718A (en) | Epcam aptamer for detection of cancer stem cells | |
EP3016715A4 (en) | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy | |
MY167652A (en) | Disposable diaper | |
IN2014DN06104A (en) | ||
MX2015014344A (en) | Cancer therapy. | |
MX2015007727A (en) | 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof. | |
MX2014001810A (en) | Use of ccne2 as a stratification marker in the treatment of breast tumours with novel pan-cdk inhibitors. | |
MX2013011694A (en) | Taxane and abeo-taxane analogs. |